NEJM: The prevention effect of the new coronary pneumonia vaccine against the Omicron (B.1.1.529) variant strain is reduced, and it is urgent to receive the "third shot"

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.
1.
1.
529 variant first identified in Botswana and South Africa on 26 November 2021 by the WHO SARS-CoV-2 Virus Evolution Technical Advisory Group Named Omicron , and then Omicron became the culprit of the new crown pneumonia epidemic in South Africa .
Early evidence suggests that Omicron can lead to an increased risk of reinfection in newly infected people .
Recently, researchers examined the efficacy of mRNA vaccines against Omicron variants .

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.

1.
1.
529 variant first identified in Botswana and South Africa on 26 November 2021 by the WHO SARS-CoV-2 Virus Evolution Technical Advisory Group Named Omicron , and then Omicron became the culprit of the new crown pneumonia epidemic in South Africa .

We used a negative case-control design to assess the impact of the vaccine on the Omicron and Delta (B.

1.
617.

immunity

Between November 27 , 2021 , and January 12 , 2022 , a total of 886,774 patients infected with OmiCon variant strains, 204,154 patients with Delta variant strains , and 1,572,621 nucleic acid negative controls were screened .
The vaccine was more effective at preventing symptomatic disease in the Delta variant than the Omicron variant in all participants .
After completing two doses of ChAdOx1 nCoV-19, its efficacy against Omicron variant was not observed within 20 weeks, while after two doses of BNT162b2 vaccination, its efficacy in preventing symptomatic disease caused by Omicron variant was 2 It was 65.
5% by 4 weeks, dropping to 8.
8% after 25 weeks or more .
In people who completed 2 ChAdOx1 nCoV-19 vaccinations, vaccine effectiveness increased to 62.
4% 2 to 4 weeks after BNT162b2 booster, and decreased to 39.
6% after 10 weeks or more .
After completing 2 BNT162b2 vaccinations, the vaccine effectiveness increased to 67.
2% after 2 to 4 weeks of BNT162b2 booster, and decreased to 45.
7% after 10 weeks or more.

Vaccine effectiveness increased to 70.
1% in ChAdOx1 nCoV-19-naïve populations 2 to 4 weeks after mRNA-1273 booster vaccination and decreased to 60.
9% at 5 to 9 weeks

Between November 27 , 2021 , and January 12 , 2022 , a total of 886,774 OmiCon variant - infected patients, 204,154 Delta variant-infected patients, and 1,572,621 nucleic acid negative controls were screened .

Increased efficacy of vaccine against Omicron after booster vaccination

Increased efficacy of vaccine against Omicron after booster vaccination

The study found that the vaccine had limited protection against symptomatic disease caused by the Omicron variant in people who completed two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccination
.

After completion of the initial immunization, vaccination with BNT162b2 or mRNA-1273 boosters significantly increased protection, but the protection diminished over time

The vaccine had limited protection against symptomatic disease caused by the Omicron variant in people who completed two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccination

Original source:

Nick Andrews et al.

Covid-19 Vaccine Effectiveness against the Omicron (B.
1.
1.
529) Variant.
Leave a Comment